Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents.
about
COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitroPreadministration of High-Dose Salicylates, Suppressors of NF- B Activation, May Increase the Chemosensitivity of Many Cancers: An Example of Proapoptotic Signal Modulation TherapyThe selective Cox-2 inhibitor Celecoxib suppresses angiogenesis and growth of secondary bone tumors: an intravital microscopy study in miceCancer drug resistance: redox resetting renders a wayIncreased Oxidative Stress as a Selective Anticancer TherapyNon steroidal anti-inflammatory drugs and COX-2 inhibitors as anti-cancer therapeutics: hypes, hopes and realityInhibition mechanism of the intracellular transporter Ca2+-pump from sarco-endoplasmic reticulum by the antitumor agent dimethyl-celecoxibIdentification and characterization of a novel integrin-linked kinase inhibitorNovel Actions of Nonsteroidal Anti-Inflammatory Drugs on Vascular Ion Channels: Accounting for Cardiovascular Side Effects and Identifying New Therapeutic Applications.From COX-2 inhibitor nimesulide to potent anti-cancer agent: synthesis, in vitro, in vivo and pharmacokinetic evaluation.An overview of the key routes to the best selling 5-membered ring heterocyclic pharmaceuticals.Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus.Synthesis and evaluation of the anti-inflammatory properties of selenium-derivatives of celecoxib.Combined effects of cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian carcinoma in vivo.Celecoxib analogs that lack COX-2 inhibitory function: preclinical development of novel anticancer drugs.Celecoxib extends C. elegans lifespan via inhibition of insulin-like signaling but not cyclooxygenase-2 activity.Celecoxib pathways: pharmacokinetics and pharmacodynamics.T-helper cell intrinsic defects in lupus that break peripheral tolerance to nuclear autoantigens.A 4-trifluoromethyl analogue of celecoxib inhibits arthritis by suppressing innate immune cell activationCelecoxib and Bcl-2: emerging possibilities for anticancer drug design.Cardiovascular risk with cyclooxygenase inhibitors: general problem with substance specific differences?Celecoxib decreases expression of the adhesion molecules ICAM-1 and VCAM-1 in a colon cancer cell line (HT29).Cyclooxygenase-2 (COX-2)-independent anticarcinogenic effects of selective COX-2 inhibitors.Effects of combining Taxol and cyclooxygenase inhibitors on the angiogenesis and apoptosis in human ovarian cancer xenografts.Cyclooxygenase-2 (COX-2): a molecular target in prostate cancer.Endoplasmic reticulum stress: its role in disease and novel prospects for therapy.Cyclooxygenase inhibitors: scope of their use and development in cancer chemotherapy.COX-Independent Mechanisms of Cancer Chemoprevention by Anti-Inflammatory Drugs.Protective Effect of Pistacia lentiscus Oil Against Bleomycin-Induced Lung Fibrosis and Oxidative Stress in Rat.NSAIDs: Old Drugs Reveal New Anticancer Targets.Rapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway.Effects of celecoxib treatment over the AKT pathway in head and neck squamous cell carcinoma.Anticancer activity and quantitative-structure activity relationship (QSAR) studies of a series of antioxidant/anti-inflammatory aryl-acetic and hydroxamic acids.OSU03012 activates Erk1/2 and Cdks leading to the accumulation of cells in the S-phase and apoptosis.A celecoxib derivative inhibits focal adhesion signaling and induces caspase-8-dependent apoptosis in human acute myeloid leukemia cells.3-Phosphoinositide-dependent protein kinase-1/Akt signalling and inhibition in a canine prostate carcinoma cell line.Celecoxib inhibits urokinase-type plasminogen activator (uPA) production in MDA-MB-231 breast cancer cells.Death receptor regulation and celecoxib-induced apoptosis in human lung cancer cells.Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation.Combined Inhibition of Epidermal Growth Factor Receptor and Cyclooxygenase-2 as a Novel Approach to Enhance Radiotherapy.
P2860
Q21245723-4B2C3172-02EE-422B-B6C6-4E02796FFFF3Q22299231-418B7560-CBBB-4607-99DB-E3BF3A438D60Q25255790-C7E38CD8-3864-4B70-B03D-7364758ACA9CQ26750753-AFB3549A-D776-45E8-9CB9-85DEA2E85394Q26798210-38CFFDD0-77DF-4410-9C0E-7445A4054591Q28166312-AC0B2FDA-E36B-440A-BBD8-CAC8C9179220Q28540515-C406D288-7801-4D00-A7A7-4698A85C213FQ33985104-967905A5-7198-48EE-9542-4A07A3102AEAQ34043009-2355EC0E-ACC0-406E-A035-D020595D9E7BQ34084150-D92295D3-0A9D-4A34-8391-2FBD321D814FQ34190368-FE760D61-DA72-449A-9362-F16C78173486Q34323128-D7BA66F7-4D51-41A5-9DF1-0206FF2EF11DQ34417632-12257BC6-BFCC-49CE-B976-D4955BDA65EBQ34578154-0E038FC7-4C9F-4F23-9A45-B1CDB6F40B1CQ34743086-91677D25-1521-49DF-B56C-EDA4FE49672BQ34981283-1CB24EBE-62B1-4559-8F5D-1D3207AF49C3Q35830941-15E0A48C-439E-4F5D-AD47-4FE3284257CDQ35998853-3139D93F-ABBB-47A9-87EA-1B26465103D4Q36084902-6B95D7DD-3FEA-4F8F-90F2-F3B71ABDE6E7Q36100952-7D69D6D8-2F10-4E3B-BE93-07D3447289ECQ36439704-5CDA86EE-865C-44FB-A651-8899DD41C120Q36495162-C42BEEC5-6CDB-48BB-BCED-612D70CB2741Q36498885-768B7174-E869-4104-833F-C234D1C665E4Q36621133-9AAFC516-5A67-4DA3-AD3D-1402F433336AQ37022652-32426E17-42BB-4095-98D6-5DE1574484A3Q37288073-BB5E7004-7C38-44E3-B6FF-26C4E306FF2BQ37646513-B46C41BF-4BC0-461E-9061-C790BEAEA2A3Q38123175-6AB10A82-BB9B-4C08-A971-3980492E2981Q38911679-C36A4F3B-B730-4AF9-98F0-960628D79FCEQ38974324-2A34B070-37AA-44B1-B114-4151DFC1A3E2Q39010100-999DD0C2-B9A4-4CD2-964F-61573C2FA66BQ39151201-E106DEED-C5E8-4E62-A0E5-A5B8C3EC88FDQ39809065-124BC35B-21D3-4F0D-A34F-8ABB54093271Q39938874-7C87C5EC-9821-4781-BF0D-C23082576AFCQ39993784-043553E4-42A8-40F8-99F9-F3A47CD38B44Q40165886-5E1ACDDF-405D-40FA-8FF4-692AFDB7A19AQ40371314-C08274F3-D128-48AC-B03F-1A18D25319B4Q40486081-2FAB9471-1874-4A8D-AD1B-381C7BEE8EB6Q40571173-FC03EBF3-1050-4992-8828-DC2AF80CE859Q41373171-A4748AE7-D25E-4EF5-9D0C-39BBACF376A5
P2860
Using cyclooxygenase-2 inhibitors as molecular platforms to develop a new class of apoptosis-inducing agents.
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
name
Using cyclooxygenase-2 inhibit ...... of apoptosis-inducing agents.
@ast
Using cyclooxygenase-2 inhibit ...... of apoptosis-inducing agents.
@en
Using cyclooxygenase-2 inhibit ...... of apoptosis-inducing agents.
@nl
type
label
Using cyclooxygenase-2 inhibit ...... of apoptosis-inducing agents.
@ast
Using cyclooxygenase-2 inhibit ...... of apoptosis-inducing agents.
@en
Using cyclooxygenase-2 inhibit ...... of apoptosis-inducing agents.
@nl
prefLabel
Using cyclooxygenase-2 inhibit ...... of apoptosis-inducing agents.
@ast
Using cyclooxygenase-2 inhibit ...... of apoptosis-inducing agents.
@en
Using cyclooxygenase-2 inhibit ...... of apoptosis-inducing agents.
@nl
P2093
P356
P1476
Using cyclooxygenase-2 inhibit ...... of apoptosis-inducing agents.
@en
P2093
Ching-Shih Chen
Donn C Young
Jiuxiang Zhu
Shunqi Yan
Victor E Marquez
Xueqin Song
P304
P356
10.1093/JNCI/94.23.1745
P407
P577
2002-12-01T00:00:00Z